Current views on the pathogenesis and treatment of atopic dermatitis in adults. Experience with the JAK inhibitor baricitinib in patients with moderate to severe atopic dermatitis
https://doi.org/10.21518/2079-701X-2022-16-6-193-201
Abstract
Atopic dermatitis is a common, chronic, immunoinflammatory disease, the study of the pathogenesis of which has recently stepped forward and served as the impetus for the development of new drugs. For the last 10–15 years, in clinical practice, the choice of therapy for patients with moderate and severe atopic dermatitis, which would provide a stable positive effect and possess a favorable safety profile for patients, including those with comorbidities, has become a rather pressing problem. The main links in the pathogenesis of atopic dermatitis and an approach to the management of adult patients with moderate to severe atopic dermatitis are considered. The role of JAK and the JAK-STAT signaling pathway in the mechanisms of inflammation in atopic dermatitis is discussed. The article presents two clinical cases of successful treatment of patients with moderate to severe atopic dermatitis with the JAK inhibitor baricitinib, who had an insufficient response to standard baseline anti-inflammatory therapy. The first case involved the treatment of a 32-year-old patient, who had been ill since early childhood, followed by a long remission and exacerbation in 2016 when the disease began to have a frequent relapsing character. In the second case, a 45-year-old patient had had frequent relapses since the age of 16. Fast and stable results in both cases were achieved with treatment with baricitinib. The drug showed a favorable safety profile and satisfactory tolerability.
About the Authors
E. V. Svechnikova
Polyclinic No. 1 of the Administration of the President of the Russian Federation;
Novosibirsk State Medical University
Russian Federation
Russian Federation
Dr. Sci. (Med.), Professor, Chief Department of Dermatovenerology and Cosmetology, 26/28, Sivtsev Vrazhek Lane, Moscow, 119002;
Professor of Department of Dermatovenereology and Cosmetology, 52, Krasny Ave., Novosibirsk, 630091
S. E. Zhufina
Polyclinic No. 1 of the Administration of the President of the Russian Federation
Russian Federation
Russian Federation
Dermatovenerologist, Department of Dermatovenerology and Cosmetology,
26/28, Sivtsev Vrazhek Lane, Moscow, 119002
E. Yu. Evdokimov
Central Research Institute of Epidemiology of The Federal Service on Customers’ Rights Protection and Human Well-being Surveillance;
Polyclinic No. 1 of the Administration of the President of the Russian Federation
Russian Federation
Russian Federation
Cand. Sci. (Med.), Researcher, Clinical Department, 3a, Novogireevskaya St., Moscow, 111123;
Dermatovenerologist, Department of Dermatovenerology and Cosmetology, 26/28, Sivtsev Vrazhek Lane, Moscow, 119002
References
1. Melo A., Carrascosa J., Torres T. Baricitinib for the treatment of atopic dermatitis. J Derm Treatment. 2021:1–10. https://doi.org/10.1080/09546634.2021.1967268.
2. Yang Ting-Lin B., Kim B.S. Clinical Review: Pruritus in Allergy and Immunology. J Allergy Clin Immunol. 2019;144(2):353–360. https://doi.org/10.1016/j.jaci.2019.06.016.
3. Hay R.J., Johns N.E., Williams H.C., Bolliger I.W., Dellavalle R.P., Margolis D.J. et al. The global burden of skin disease in 2010: An analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1527–1534. https://doi.org/10.1038/jid.2013.446.
4. Barbarot S., Auziere S., Gadkari A., Girolomoni G., Puig L., Simpson E.L. et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284–1293. https://doi.org/10.1111/all.13401.
5. Werfel T., Allam J.P., Biedermann T., Eyerich K., Gilles S., Guttman-Yassky E. et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138:336–349. https://doi.org/10.1016/j.jaci.2016.06.010.
6. Rodrigues M., Torres T. The Changing Landscape of Atopic Dermatitis – Focusing on JAK Inhibitors. Eur Ann Allergy Clin Immunol. 2020;52(1):45–48. https://doi.org/10.23822/EurAnnACI.1764-1489.120.
7. Damsky W., King B. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736–744. https://doi.org/10.1016/j.jaad.2016.12.005.
8. Gonzales A.J., Bowman J.W., Fici G.J., Zhang M., Mann D.W., Mitton-Fry M. Oclacitinib (APOQUEL((R))) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014;37(4):317–324 https://doi.org/10.1111/jvp.12101.
9. Tikhomirov T.A., Fedorova N.I., Korotkiy V.N., Tikhomirov A.A., Dmitrenko O.A. Microbiological features of inflammatory process in various ecotopes in children with atopic dermatitis. Klinicheskaya Dermatologiya i Venerologiya. 2016;(3):43–47. (In Russ.) https://doi.org/10.17116/klinderma201615343-47.
10. Szalus K., Trzeciak M., Nowicki R. JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results. Microorganisms. 2020;8(11):1743. https://doi.org/10.3390/microorganisms8111743.
11. Svechnikova E.V., Marshani Z.B., Ushakova D.V., Ojnotkinova O.Sh. Dupilumab in the clinical practice: Clinical case of severe atopic dermatitis. Klinicheskaya Dermatologiya i Venerologiya. 2019;18(6):768–775. (In Russ.) https://doi.org/10.17116/klinderma201918061768.
12. Silverberg J.I., Gelfand J.M., Margolis D.J., Boguniewicz M., Fonacier L., Grayson M.H. et al. Atopic dermatitis in US adults: from population to health care utilization. J Allergy Clin Immunol Pract. 2019;7(5):1524–1532.e2. https://doi.org/10.1016/j.jaip.2019.01.005.
13. Boguniewicz M., Fonacier L., Guttman-Yassky E., Ong P.Y., Silverberg J., Farrar J.R. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10–22.e2. https://doi.org/10.1016/j.anai.2017.10.039.
14. Traidl S., Freimooser S., Werfel T. Janus kinase inhibitors for the therapy of atopic dermatitis. Allergologie Select. 2021;5(1):293–304. https://doi.org/10.5414/ALX02272E.
15. Politiek K., van der Schaft J., Coenraads P.J., de Bruin-Weller M.S., Schuttelaar M.L.A. Drug survival for methotrexate in a daily practice cohort of adult patients with severe atopic dermatitis. Br J Dermatol. 2016;174(1):201–203. https://doi.org/10.1111/bjd.13961.
16. Eichenfield L., Stein Gold L. Addressing the Immunopathogenesis of Atopic Dermatitis: Advances in Topical and Systemic Treatment. Semin Cutan Med Surg. 2017;36(2):45–48. https://doi.org/10.12788/j.sder.2017.012.
17. Reich K., Kabashima K., Peris K., Silverberg J., Eichenfield L., Bieber T. et al. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis. JAMA Dermatol. 2020;156(12):1–11. https://doi.org/10.1001/jamadermatol.2020.3260.
18. Reich K. Long-term safety of guselkumab in patients with moderate to severe plaque psoriasis: Integrated data through Week 156 of the Phase 3 VOYAGE 1 and VOYAGE 2 trials. Abstract FC02.01. EADV Congress, 9–13 October, 2019. EMJ Dermatol. 2019;7(10 Suppl.):10–16. Available at: https://www.emjreviews.com/dermatology/symposium/latesthighlights-from-guselkumab-in-psoriasis-from-eadv-2019.
Review
For citations:
Svechnikova EV, Zhufina SE, Evdokimov EY. Current views on the pathogenesis and treatment of atopic dermatitis in adults. Experience with the JAK inhibitor baricitinib in patients with moderate to severe atopic dermatitis. Meditsinskiy sovet = Medical Council. 2022;(6):193-201. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-6-193-201
Views:
689
Email this article 